이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Touchstone International Medical Science 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Wangdong Chen

최고 경영자

CN¥1.1m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	26.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Capital Allocation Trends At Touchstone International Medical Science (SHSE:688013) Aren't Ideal

Jun 07

Improved Earnings Required Before Touchstone International Medical Science Co., Ltd. (SHSE:688013) Stock's 25% Jump Looks Justified

Mar 06

CEO

Wangdong Chen (54 yo)

no data

테뉴어

CN¥1,055,500

보상

Mr. Wangdong Chen serves as Director and General Manager at Touchstone International Medical Science Co., Ltd.

Touchstone International Medical Science 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Touchstone International Medical Science Co., Ltd., Annual General Meeting, Jun 05, 2024

No independent directors

No independent directors

Recent updates

Touchstone International Medical Science Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Capital Allocation Trends At Touchstone International Medical Science (SHSE:688013) Aren't Ideal

Touchstone International Medical Science Co., Ltd., Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: EPS: CN¥0.60 (vs CN¥0.54 in FY 2022)

Investor sentiment deteriorates as stock falls 20%

New minor risk - Share price stability

Touchstone International Medical Science Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Improved Earnings Required Before Touchstone International Medical Science Co., Ltd. (SHSE:688013) Stock's 25% Jump Looks Justified

Full year 2023 earnings released: EPS: CN¥0.65 (vs CN¥0.54 in FY 2022)

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 15%

Touchstone International Medical Science Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.08 (vs CN¥0.16 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in 2Q 2022)

Touchstone International Medical Science Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Upcoming dividend of CN¥0.25 per share at 1.1% yield

Full year 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.52 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.52 in FY 2021)

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.16 in 1Q 2021)

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Touchstone International Medical Science Co., Ltd. (SHSE:688013) announces an Equity Buyback for CNY 100 million worth of its shares.

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.70 in FY 2019)

Touchstone International Medical Science Co., Ltd. to Report Fiscal Year 2020 Results on Mar 15, 2021

New 90-day low: CN¥25.23

New 90-day low: CN¥25.26

Investor sentiment deteriorated over the past week

New 90-day low: CN¥29.31

Touchstone International Medical Science Co., Ltd. has completed an IPO in the amount of CNY 372.4 million.

CEO

테뉴어

보상